Equine proBNP antibody and antigen (recombinant protein)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-EQU-proBNP-Ag01	Recombinant Equine proBNP protein	3090
GMP-EQU-proBNP-Ab01	Anti-Equine proBNP mouse monoclonal antibody (mAb)	1953
GMP-EQU-proBNP-Ab02	Anti-Equine proBNP mouse monoclonal antibody (mAb)	1953
GMP-EQU-proBNP-Ab03	Anti-Equine proBNP human monoclonal antibody (mAb)	1953
GMP-EQU-proBNP-Ab04	Anti-Equine proBNP human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-EQU-proBNP-Ag01
Product Name	Recombinant Equine proBNP protein
Target/Biomarker	Equine Pro B-Type Natriuretic Peptide (proBNP)
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Equine Pro B-Type Natriuretic Peptide antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in proBNP level test of animal Equine/Horse with intrinsic cardiac dysfunction.
Tag	His
Products description	Recombinant Equine proBNP protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-EQU-proBNP-Ab01, GMP-EQU-proBNP-Ab02
Product Name	Anti-Equine proBNP mouse monoclonal antibody (mAb)
Target/Biomarker	Equine Pro B-Type Natriuretic Peptide (proBNP)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Equine Pro B-Type Natriuretic Peptide antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-proBNP antibodies in proBNP level test of animal Equine/Horse with intrinsic cardiac dysfunction.
Tag	mFc
Products description	Anti-Equine proBNP mouse monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-proBNP antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-EQU-proBNP-Ab03, GMP-EQU-proBNP-Ab04
Product Name	Anti-Equine proBNP human monoclonal antibody (mAb)
Target/Biomarker	Equine Pro B-Type Natriuretic Peptide (proBNP)
Expression platform	CHO
Isotypes	Human IgG1
Bioactivity validation	Recombinant Equine Pro B-Type Natriuretic Peptide antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-proBNP antibodies in proBNP level test of animal Equine/Horse with intrinsic cardiac dysfunction.
Tag	hFc
Products description	Anti-Equine proBNP human monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-proBNP antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

B-type natriuretic peptide (BNP) is a cardiac hormone that plays a key role in regulating the cardiovascular system. It is primarily secreted by the ventricles of the heart in response to increased wall stress and stretch, which are often associated with conditions like heart failure or cardiac overload. BNP acts as a vasodilator, meaning it helps to widen blood vessels, and promotes diuresis, which increases the excretion of salt and water through urine. These actions help reduce the workload of the heart and alleviate the symptoms of cardiac dysfunction. In horses, proBNP is the inactive precursor of BNP and is synthesized and stored in cardiomyocytes, the heart muscle cells. When the heart undergoes excessive stretching or pressure overload, such as in cases of myocardial dysfunction or valvular diseases, proBNP is cleaved into its active form, BNP. This cleavage process is catalyzed by an enzyme called corin. Once released into the bloodstream, BNP acts on receptors in various tissues, including blood vessels and the kidneys, exerting its physiological effects. The production and release of proBNP and BNP are tightly regulated processes. Multiple factors influence their synthesis, including mechanical stress on the heart, neurohormonal factors, and genetic variations. For example, increased wall stress due to an enlarged heart or high blood pressure triggers the release of proBNP, which then undergoes enzymatic cleavage to produce active BNP. On the other hand, conditions such as low blood pressure or dehydration can decrease the synthesis and secretion of proBNP and BNP. Researchers have identified specific proBNP fragments that exhibit differential expression patterns in various cardiac conditions. By measuring the levels of these fragments, veterinarians can gain a more comprehensive understanding of the underlying cardiac pathology. For instance, in horses with congestive heart failure, elevated proBNP levels indicate the severity of the disease and can help monitor the response to treatment. By contrast, reduced proBNP levels may signify an improvement in cardiac function. To measure proBNP levels, advanced techniques such as immunoassays and mass spectrometry are employed. Immunoassays use specific antibodies that recognize and bind to proBNP or its fragments, allowing their quantification in a sample. Mass spectrometry is a sensitive analytical technique that can precisely measure the mass and concentration of proBNP peptides in equine plasma or serum. These methods enable accurate and reliable assessment of proBNP concentrations, aiding in the diagnosis and management of cardiac disorders in horses.

About GDU